TABLE 1.
Baseline characteristics of the 3 cohorts associated with the panels used in part 1 of the study, including 452 samples with positive SARS-CoV-2 RNA detection by RT-PCR and 526 samples not containing SARS-CoV-2 RNA
| Cohort/panel and characteristic | No. (%) of samples | ||
|---|---|---|---|
| Cohort/panel 1 | SARS-CoV-2 RNA positive (n = 152)a | SARS-CoV-2 RNA negative (n = 150)b | SARS-CoV-2 RNA negative in transparent VTM (n = 101)c |
| Days from symptom onset | |||
| ≤3 | 56 (36.8) | ||
| 4–7 | 14 (9.2) | ||
| 8–11 | 7 (4.6) | ||
| ≥12 | 7 (4.6) | ||
| Asymptomatic | 20 (13.2) | ||
| Unknown | 48 (31.6) | ||
| RT-PCR CT value | |||
| ≤20 | 21 (13.8) | ||
| 21–25 | 46 (30.3) | ||
| 26–30 | 38 (25.0) | ||
| >30 | 47 (30.9) | ||
| Other pathogens detected | |||
| None | 74 (49.3) | NT | |
| Virald | 76 (50.7) | NT | |
| Cohort/panel 2 | SARS-CoV-2 RNA positive (n = 150) | SARS-CoV-2 RNA negative (n = 125) | |
| Days from symptom onset | |||
| ≤3 | 19 (12.7) | ||
| 4–7 | 18 (12.0) | ||
| 8–11 | 13 (8.7) | ||
| ≥12 | 5 (3.3) | ||
| Asymptomatic | 3 (2.0) | ||
| Unknown | 92 (61.3) | ||
| RT-PCR CT value | |||
| ≤20 | 21 (14.0) | ||
| 21–25 | 46 (30.7) | ||
| 26–30 | 38 (25.3) | ||
| >30 | 45 (30.0) | ||
| Other pathogens detected | |||
| None | 100 (80.0) | ||
| Virale | 25 (20.0) | ||
| Cohort/panel 3 | SARS-CoV-2 RNA positive (n = 150) | SARS-CoV-2 RNA negative (n = 150) | |
| Days from symptom onset | |||
| ≤3 | 25 (16.7) | ||
| 4–7 | 22 (14.8) | ||
| 8–11 | 20 (13.3) | ||
| ≥12 | 5 (3.3) | ||
| Asymptomatic | 1 (0.6) | ||
| Unknown | 77 (51.3) | ||
| RT-PCR CT value | |||
| ≤20 | 21 (14.0) | ||
| 21–25 | 46 (30.7) | ||
| 26–30 | 32 (21.3) | ||
| >30 | 51 (34.0) | ||
| Other pathogens detected | |||
| None | 124 (82.7) | ||
| Virale | 26 (17.3) | ||
Sofia and Wantai LFTs could be evaluated with only a subset of this cohort (n = 133 and n = 118, respectively), due to possible interference between VTM and automatic immunofluorescence reading.
This panel could not be used to assess the specificity of Sofia and Wantai LFTs, due to possible interference between VTM and automatic immunofluorescence reading.
This additional panel was collected on transparent VTM to assess the specificity of Sofia and Wantai LFTs to avoid interference with automatic immunofluorescence. NT, not tested.
Coronaviruses other than SARS-CoV-2 were detected in 12 patients, including HKU1 (n = 3), NL63 (n = 3), 229E (n = 3), and OC43 (n = 3).
Coronaviruses other than SARS-CoV-2 were detected in 8 patients, including HKU1 (n = 2), NL63 (n = 2), 229E (n = 2), and OC43 (n = 2).